Key points are not available for this paper at this time.
Background: Cannabinoids are studied as anticancer agents, but their effects vary across tumors, compounds, and experimental settings, underscoring the need to define consistent patterns. Our objective was to map cannabinoid efficacy across cancer preclinical models and identify tumor settings with the greatest translational promise. Methods: The protocol was registered on PROSPERO (CRD42025543744); PubMed, Embase, and CENTRAL were searched on 4 April 2024 for in vitro and in vivo studies assessing cannabinoid antitumor effects alone or with chemotherapy versus vehicle or chemotherapy only. Random-effects models yielded pooled mean differences (MD) with 95% confidence intervals (CI). MDs of viable cells were calculated for in vitro assays and tumor volume (mm3) for in vivo studies. Reports of various compounds, cannabidiol (CBD), tetrahydrocannabinol (THC) or synthetic cannabinoids, were pooled. Results: We included 189 studies in the final analysis. In vitro, cannabinoids reduced cell viability modestly overall, with significant effects in glioblastoma (MD −18.77 CI: −27.15; −10.39) and a nonsignificant trend in breast cancer (MD −6.75 CI: −13.90; 0.40). For in vivo, monotherapy showed the most consistent efficacy in glioblastoma, significantly reducing tumor volume by MD −980.58 mm3; CI: −1270.2; −690.88. Addition to temozolomide produced a favorable but nonsignificant decrease of MD −220.65 mm3; CI: −579.34; 138.03, vs. temozolomide. In breast cancer, cannabinoids achieved smaller yet significant tumor reductions (MD −402.64 mm3); CI: −671.84; −133.45. Synthetic agents had the largest effect (MD −1295.19 mm3); CI: −1664.33; −928.05 -CBD plus doxorubicin vs. doxorubicin). Lung cancer (MD −562.17 mm3); CI: −693.99; −430.35 and prostate cancer (MD −1136.59 mm3); 95% CI: −1320.97; −952.21 also had a significant response, whereas colon, pancreatic, and hepatocellular carcinoma models showed inconsistent or null responses. Conclusions: Cannabinoids show promise as adjuncts in oncotherapy, particularly in glioblastoma and breast cancer, to enhance chemotherapy efficacy. These findings should be interpreted with caution given the high inter-study heterogeneity typical of preclinical research and should be considered hypothesis-generating, warranting further validation in standardized and clinically relevant models.
Creangă-Murariu et al. (Thu,) studied this question.